Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of VB6-845d

Trial Profile

A phase I study of VB6-845d

Phase of Trial: Phase I

Latest Information Update: 16 May 2018

At a glance

  • Drugs Citatuzumab bogatox (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 16 May 2018 According to a Sesen Bio media release, Eleven Biotherapeutics changed its name to Sesen Bio.
    • 23 Aug 2017 New trial record
    • 14 Aug 2017 According to an Eleven Biotherapeutics media release, the company plans to file an investigational new drug (IND) application for VB6-845d and initiate a Phase 1 trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top